Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients

Attanasio, Roberto; Mainolfi, A.; Grimaldi, Franco; Cozzi, Renato; Montini, M; Carzaniga, Chiara; Grottoli, Silvia; Cortesi, L; Albizzi, Mascia; Testa, Rm; Fatti, Letizia Maria; Giorgio, Dario; Scaroni, Carla; Cavagnini, Francesco; Loli, Paola; Pagani, Giorgio A.; Ghigo, Ezio

doi:10.1007/bf03346419

Cited by 47 publications

(42 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Independently of the type of pituitary adenoma, a strong association was found between SSA therapy and the devel-opment of gallstones (confirming the literature data [23]) and kidney stones. Several mechanisms for which SSA contribute to gallstones formation have been postulated, leading to increased bile concentration and lithogenic changes in its composition, together with physical conditions favoring micro-crystal precipitation and stone for-mation.…”

Section: Discussionsupporting

confidence: 84%

Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up

Guaraldi

Gori

Beccuti

et al. 2016

J Endocrinol Invest

Self Cite

View full text Add to dashboard Cite

validity 2 AbstractPurpose To determine the validity of a self-administered questionnaire (Acro-CQ) developed to systematically assess the presence, type and time of onset of acromegaly comorbidities.Methods This is a cross-sectional study; 105 acromegaly patients and 147 controls with other types of pituitary adenoma, referred to a specialized Italian Center, autonomously compiled Acro-CQ in an outpatient clinical setting. To test its reliability in a different setting, Acro-CQ was administered via mail to 78 patients with acromegaly and 100 with other pituitary adenomas, referred to a specialized US Center. Data obtained from questionnaires in both set-tings were compared with medical records (gold standard). Results Demographics of patients and controls from both countries were similar. In both settings, >95 % of the questionnaires were completely filled; only one item was missed in the others.Concordance with medical record was excellent (k > 0.85) for most of the items, independently from the way of administration, patient age, gender and nationality, pituitary adenoma type and disease activity.Conclusions Acro-CQ is an inexpensive, highly accepted from patients and reliable tool recommended to expedite systematic collection of relevant clinical data in acromeg-aly at diagnosis, to be replicated at follow-ups. This tool may guide a targeted, cost-effective management of com-plications. Moreover, it could be applied to retrieve data for survey studies in both acromegaly and other pituitary adenomas, as information is easily and rapidly accessible for statistical analysis.3

show abstract

Section: Discussionsupporting

confidence: 84%

Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up

Guaraldi

Gori

Beccuti

et al. 2016

J Endocrinol Invest

Self Cite

View full text Add to dashboard Cite

show abstract

“…15 Gallstones are commonly associated with somatostatin analogue treatment but are rarely symptomatic or require surgery. 15,25 In this study, 20% (n=15; 10mg) and 45% (n=34; 30mg) of patients had cholelithiasis; four patients underwent cholecystectomy. Gallbladder ultrasound is advised at regular intervals during pasireotide treatment.…”

Section: Discussionmentioning

confidence: 65%

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

Lacroix

Gallardo

et al. 2018

The Lancet Diabetes & Endocrinology

123

100

View full text Add to dashboard Cite

“…All hyperglycaemias were reversible and there was no symptomatic cholelithiasis in our study. However, a previous study demonstrated increased prevalence of gallstones in patients with acromegaly who were treated up to 18 years, indicating the potential risks of prolonging therapy . Three patients were suspected of hepatic or renal cyst infection during our study.…”

Section: Discussionmentioning

confidence: 66%

Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial

Gevers

Hol

Monshouwer

et al. 2014

Liver International

View full text Add to dashboard Cite

show abstract

Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients

Abstract: GS are a frequent occurrence in acromegalic patients treated with SA, may occur at any time, but are seldom symptomatic or prompt acute surgery. Obesity and dyslipidemia appear to play a major role in the occurrence of GS in acromegalic patients on SA treatment.

Cited by 47 publications

References 58 publications

Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up

Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial

Contact Info

Product

Resources

About